Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus NICLOCIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus NICLOCIDE.
ANTEPAR vs NICLOCIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Inhibits oxidative phosphorylation in cestodes, leading to paralysis and death of the parasite.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
2 g orally as a single dose, chewed thoroughly, for taeniasis; may repeat in 1 week for hymenolepiasis.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
The terminal elimination half-life of niclosamide is approximately 2-6 hours in patients with normal renal function; however, clinical efficacy against cestodes is prolonged due to its local action in the gastrointestinal tract.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Niclosamide is predominantly excreted in feces as unchanged drug and metabolites after oral administration. Renal excretion of metabolites accounts for less than 2% of an administered dose. Approximately 70% of the dose is recovered in feces within 2-3 days.
Category C
Category C
Anthelmintic
Anthelmintic